Anthracyclines and Biomarkers of Myocardial Injury
The Effect of Remote Ischemic Conditioning

Michael Mallouppas, MD, MBBS, Robin Chung, MPHIL, MBBS, Arjun K. Ghosh, PhD, MBBS, Alison Macklin, RGN, Derek M. Yellon, DSc, J. Malcolm Walker, MD

ABSTRACT

BACKGROUND Remote ischemic conditioning (RIC) has been beneficial in laboratory studies of anthracycline cardiotoxicity, but its effects in patients is not established.

OBJECTIVES The authors studied the effect of RIC on cardiac biomarkers and function during and after anthracycline chemotherapy.

METHODS The ERIC-Onc study (Effect of Remote Ischaemic Conditioning in Oncology Patients; NCT02471885) was a randomized, single-blind, sham-controlled study of RIC at each chemotherapy cycle. The primary endpoint was troponin T (TnT) during chemotherapy and up to 1 year. Secondary outcomes included cardiac function, major adverse cardiovascular events (MACE), and MACE or cancer death. Cardiac myosin-binding-protein C (cMyC) was investigated in parallel with TnT.

RESULTS The study was prematurely halted after the evaluation of 55 patients (RIC n = 28, sham n = 27). Biomarkers increased from baseline to cycle 6 of chemotherapy for all patients (median TnT 6 [IQR: 4-9] ng/L to 33 [IQR: 16-36] ng/L; P < 0.001; cMyC 3 [IQR: 2-5] ng/L to 47 [IQR: 18-49] ng/L; P ≤ 0.001). Mixed-effects regression analysis for repeated measures showed no difference in TnT between the 2 groups (RIC vs sham, mean difference 3.15 ng/L; 95% CI: −0.04 to 6.33; P = 0.053), or cMyC (RIC vs sham, mean difference 4.17 ng/L; 95% CI: −0.12 to 8.45; P = 0.056). There were more MACE and cancer deaths in the RIC group (11 vs 3; HR: 0.25; 95% CI: 0.07-0.90; P = 0.034), with more cancer deaths (8 vs 1; HR: 0.21; 95% CI: 0.04-0.95; P = 0.043) at 1 year.

CONCLUSIONS TnT and cMyC significantly increased during anthracycline chemotherapy with 81% having a TnT ≥14 ng/L at cycle 6. RIC did not affect the rise in biomarkers, but there was a small increase in early cancer deaths, possibly related to the greater proportion of patients with metastatic disease randomized to the RIC group (54% vs 37%). (Effect of Remote Ischaemic Conditioning in Oncology Patients [ERIC-ONC]; NCT02471885) (J Am Coll Cardiol CardioOnc 2023;5:343-355) © 2023 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Anthracyclines remain a cornerstone therapy for various cancers; however, cardiotoxicity (when defined as a 10% drop in left ventricular [LV] ejection fraction [LVEF]) occurs in up to 9% of cases. The mechanism of injury is multifactorial, and cardioprotective strategies have shown variable results. Dexrazoxane is currently the only approved therapy in patients receiving high-dose anthracyclines; however, its use has not been widespread. Remote ischemic conditioning (RIC) is a noninvasive nonpharmacological cardioprotective intervention that has been repeatedly shown in laboratory and clinical proof-of-concept studies to protect against ischemia-reperfusion injury (IRI), including the mitigation of cardiac biomarker release in some clinical studies. Anthracycline cardiotoxicity and IRI share common pathophysiological mechanisms with doxorubicin enhancing damage from IRI, and iron chelators, such as dexrazoxane, inhibiting ferroptosis that is implicated in both pathologies. Thus, RIC appears to be a potentially useful intervention to explore. Experiments in animals have shown direct benefit of RIC in anthracycline cardiotoxicity in terms of cell death, survival, troponin release, and LVEF. In this study, we investigated for the first time in cancer patients, the effect of RIC in patients receiving anthracycline chemotherapy (Effect of Remote Ischaemic Conditioning in Oncology Patients [ERIC-ONC] trial; NCT02471885).

METHODS

PATIENT POPULATION. This was a randomized, single-blind, sham-controlled phase II trial performed at University College London Hospitals (UCLH) in accordance with the Declaration of Helsinki and received ethics approval from the local National Health Service Health Research Authority. Patients aged 16 to 80 years, with any cancer, who were designated to receive anthracycline-containing chemotherapy, were recruited. Exclusion criteria were reported previously and summarized in Supplemental Table 1; chemotherapy is described in Supplemental Table 2.
Randomization was performed 1:1 into a RIC or sham group using randomization software (MinimPy Version 0.3) with minimization for coronary artery disease, treated hypertension, and diabetes.

Study protocol. The study protocol is shown in Figure 1.

PROCEDURES. Intervention protocols. At each chemotherapy session, a blood pressure cuff was applied onto a patient’s arm and connected to an automated RIC machine17 that, before anthracycline dosing, inflated the cuff to a pressure of 200 mm Hg (or 30 mm Hg above systolic if not tolerated or if platelets were between $5 \times 10^9$/L and $100 \times 10^9$/L) for 5 minutes followed by 5 minutes of reperfusion for a total of 4 cycles. If platelets were $<50 \times 10^9$/L on the day, then the RIC was omitted on that occasion. For the sham protocol, the cuff was inflated to 10 mm Hg for 5 minutes, then deflated for 4 cycles. The study clinicians (M.M., R.C., A.K.G., and J.M.W.) were blinded to the RIC intervention, but it is acknowledged that patient blinding to RIC vs sham is difficult to achieve and thus not assumed. Data were analyzed blinded to the treatment group.

Cardiac biomarkers. Blood samples for high-sensitivity troponin T (TnT), and cardiac myosin-binding protein C (cMyC) were collected immediately before each RIC application and between 3 to 24 hours after the end of each anthracycline infusion. TnT was measured by a standardized high-sensitivity assay, Elecsys (Roche) with a 10% coefficient of variation, upper limit of normal sensitivity assay, Elecsys (Roche) with a 10% coefficient of variation, upper limit of normal 14 ng/L,

<table>
<thead>
<tr>
<th>Table 1: Baseline Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>All (N = 55)</td>
</tr>
<tr>
<td>Age, y</td>
</tr>
<tr>
<td>Gender</td>
</tr>
<tr>
<td>Male</td>
</tr>
<tr>
<td>Female</td>
</tr>
<tr>
<td>Medical comorbidities</td>
</tr>
<tr>
<td>Hypertension</td>
</tr>
<tr>
<td>Diabetes</td>
</tr>
<tr>
<td>High cholesterol</td>
</tr>
<tr>
<td>Other*</td>
</tr>
<tr>
<td>Smoking status</td>
</tr>
<tr>
<td>Current smoker</td>
</tr>
<tr>
<td>Former smoker</td>
</tr>
<tr>
<td>Never smoked</td>
</tr>
<tr>
<td>Family history of ischemic heart disease</td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
<tr>
<td>Baseline medications</td>
</tr>
<tr>
<td>Beta-blockers</td>
</tr>
<tr>
<td>ACE inhibitors</td>
</tr>
<tr>
<td>ARBs</td>
</tr>
<tr>
<td>CCB</td>
</tr>
<tr>
<td>Thiazides</td>
</tr>
<tr>
<td>Statins</td>
</tr>
<tr>
<td>Anticoagulants</td>
</tr>
<tr>
<td>Antidiabetic agents</td>
</tr>
<tr>
<td>PPI</td>
</tr>
<tr>
<td>Analgesics</td>
</tr>
<tr>
<td>Steroid inhalers</td>
</tr>
<tr>
<td>Steroids</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

CARDIAC BIOMARKERS. Blood samples for high-sensitivity troponin T (TnT), and cardiac myosin-binding protein C (cMyC) were collected immediately before each RIC application and between 3 to 24 hours after the end of each anthracycline infusion. TnT was measured by a standardized high-sensitivity assay, Elecsys (Roche) with a 10% coefficient of variation, upper limit of normal sensitivity assay, Elecsys (Roche) with a 10% coefficient of variation 14 ng/L, lower limit of detection 0.4 ng/L, measurement range 3 to 10,000 ng/L.8 cMyC was assayed by a dedicated laboratory,19,20 utilizing the EMD Millipore on the Erenna platform, which has a lower limit of detection of 0.4 ng/L and a lower limit of quantification (20% coefficient of variation) of 1.2 ng/L.

Echocardiography. Transthoracic echocardiography was performed (GE E6) using a standardized cardio- oncology protocol. LVEF was measured using 4-dimensional volumetric assessment and/or biplane Simpson’s method where possible, or by visual estimate otherwise. Global longitudinal strain (GLS), was measured via GE EchoPac software. Scan acquisition and analysis were undertaken by sonographers and reviewed by clinicians (M.M. and R.C.) blinded to the treatment protocol; the UCLH echo department and sonographers are European Association of Cardiovascular Imaging accredited.

Arrhythmia monitoring. Extended electrocardiogram (ECG) monitoring between cycles 5 and 6 was performed for up to 14 days, using a 1-lead ambulatory electrocardiogram (Zio XT patch, iRhythm Technologies).

Primary outcome. The primary outcome was a comparison between the 2 groups of TnT up to 12 months post-chemotherapy, analyzed both as a continuous and binary (positive $[>14 \text{ ng/L}]$ vs negative) variable.

The acute effect of anthracyclines and possible effect of RIC on TnT was investigated by comparison of pre- and immediate post-chemotherapy samples, for each cycle of anthracyline treatment (Supplemental Figure 1, Supplemental Table 3).

Secondary outcomes. Cardiac myosin binding protein C. cMyC is released rapidly after acute myocardial injury, and has not been studied in patients receiving anthracyclines. We hypothesized that cMyC might be more sensitive and detected earlier than troponin. Following a study protocol
ethics amendment, 22 patients consented to have cMyC analysis. Using pre-chemotherapy samples, the ratio of peak to baseline concentration as well as the ratio at each cycle were compared for each group.

<table>
<thead>
<tr>
<th>TABLE 1 Continued</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Cancer and chemotherapy baseline details</td>
</tr>
<tr>
<td>Cancer type</td>
</tr>
<tr>
<td>Sarcoma</td>
</tr>
<tr>
<td>Breast</td>
</tr>
<tr>
<td>Lymphoma</td>
</tr>
<tr>
<td>Metastatic</td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>Cancer diagnosis type</td>
</tr>
<tr>
<td>New</td>
</tr>
<tr>
<td>Relapse</td>
</tr>
<tr>
<td>Anthracycline type</td>
</tr>
<tr>
<td>Doxorubin</td>
</tr>
<tr>
<td>Epirubin</td>
</tr>
<tr>
<td>Chemotherapy regimen</td>
</tr>
<tr>
<td>Dox</td>
</tr>
<tr>
<td>D-Ifos</td>
</tr>
<tr>
<td>FEC-PC</td>
</tr>
<tr>
<td>D-Cis</td>
</tr>
<tr>
<td>D-Ola</td>
</tr>
<tr>
<td>RCHOP</td>
</tr>
<tr>
<td>MAP</td>
</tr>
<tr>
<td>VI-Dox</td>
</tr>
<tr>
<td>FEC-DT</td>
</tr>
<tr>
<td>CHOEP</td>
</tr>
<tr>
<td>CHOP</td>
</tr>
<tr>
<td>IVA-Dox</td>
</tr>
<tr>
<td>RCHOP-Mtx</td>
</tr>
<tr>
<td>VIDE</td>
</tr>
<tr>
<td>VDCIE</td>
</tr>
<tr>
<td>FEC-D</td>
</tr>
<tr>
<td>ECOG WHO performance status</td>
</tr>
<tr>
<td>0</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>Unknown</td>
</tr>
<tr>
<td>Total chemotherapy cycles received</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>5</td>
</tr>
<tr>
<td>6</td>
</tr>
<tr>
<td>Total cumulative anthracyline dose received, mg/m2</td>
</tr>
<tr>
<td>Method of administration</td>
</tr>
<tr>
<td>Slow bolus</td>
</tr>
<tr>
<td>46-h infusion</td>
</tr>
<tr>
<td>Both</td>
</tr>
</tbody>
</table>

Echocardiographic parameters. The change in LVEF (ΔLVEF) from baseline to 3 and 12 months (3M and 12M, respectively), and the change in GLS (ΔGLS and relative percentage change in GLS) from baseline to 3M and 12M post-chemotherapy was compared between the 2 groups.

NT-proBNP. The change in N-terminal pro-B-type natriuretic peptide (NT-proBNP; ΔNT-proBNP) from baseline to 3M post-chemotherapy was compared between the 2 groups.

CLINICAL OUTCOMES. Major adverse cardiovascular events (MACE) from enrollment to 12M follow-up were defined as follows: myocardial infarction, heart failure (HF) or asymptomatic LV dysfunction needing hospitalization or initiation of HF medications, life-threatening tachyarrhythmia needing treatment or bradyarrhythmia requiring pacing, and cardiac death. Deaths from any cause, and serious adverse events defined as any infection, venous thromboembolic event, anemia requiring transfusion, gastroesophageal reflux disease, epistaxis, or back pain were recorded (Supplemental Table 4).

Events were adjudicated by study clinicians (J.M.W., A.K.G., and R.C.) blinded to the treatment groups and reviewed by an independent data monitoring committee (DMC).

ARRHYTHMIA INCIDENCE. The incidence of arrhythmia during chemotherapy was assessed using the 14-day ECG and defined according to published guidelines.21

SAMPLE SIZE. Sample-size calculations for the study were described before16 and assumed a treatment effect of 35% with 80% power at the 5% significance level, giving a sample size of 128 (n = 64 in each arm of the study). This calculation was based on the (TnT) cardiotoxicity data in cancer patients receiving chemotherapy that was available at the time. The categorical effect of RIC on TnT was hypothesized based on studies in the context of cardiac surgery, elective stenting, and ST-segment elevation myocardial infarction, with event rate reductions between 16% and 49%.22-24

STATISTICAL ANALYSIS. Statistical analysis and graphical representation were performed with the SPSS statistical software (IBM SPSS Statistics, Version 28). Statistical significance was considered at the 5% significance level. For the primary outcome, comparison was performed with a mixed-effects model for repeated measures and presented as the least squares mean difference with 95% CI. The mixed-effects model for repeated measures included treatment arm and time point of TnT sampling as fixed-effect covariates and TnT value as the
dependent-effect covariate (with the intercept line as a random-effect covariate). Normality was assessed with Q-Q plots and Shapiro-Wilk tests for each time point of TnT sampling and each group. Summary statistics were described as mean ± SD and median with 25th and 75th percentiles (IQR) for continuous variables, and as counts and percentages for categorical variables. Between-group comparisons were made using the independent samples t-test and Mann-Whitney test for continuous data, and multinomial logistic regression for categorical data. Within-group comparisons were undertaken using the paired samples t-test and Wilcoxon signed rank test for continuous data. Time-to-event data are presented as counts and by using Kaplan-Meier plots. Kaplan-Meier estimates were compared using the log-rank test, and Cox proportional hazards models were used to estimate the HR with 95% CI. Clinical adverse events are presented as counts and percentages.

**RESULTS**

**PATIENT RECRUITMENT.** From February 2016 to February 2020, 60 patients were recruited, with 31 allocated to the RIC group and 29 to the sham group. Details of patients excluded are given in Supplemental Figure 1.

Of the 31 in the RIC group, 1 withdrew consent after randomization before chemotherapy, 1 withdrew consent after cycle 1. One patient has not been included in analyses as they were withdrawn at cycle 1 due to the precautionary halting of all clinical trial activity, including nonessential laboratory analyses (eg, nonclinical TnT) not directly related to COVID at UCLH. Of the 29 in the sham group, 2 withdrew consent after randomization but before chemotherapy. One further patient from the sham group withdrew at cycle 6 (11%) lymphoma, and 4 (7%) breast cancer; the distribution of cancer types did not differ between the RIC or sham groups. Twenty-five (46%) had metastatic disease, 54% in RIC and 37% in sham. The mean cumulative dose of doxorubicin given during this cycle of chemotherapy was 317 ± 95 mg/m² (Table 1). Baseline mean LVEF was 61% ± 4%, and baseline TnT was 6 ± 5 ng/L (full echocardiographic and laboratory baseline data are shown in Supplemental Tables 5 to 7).

**PRINCIPAL OUTCOME.** Effect of RIC on pre-chemotherapy TnT. Baseline pre-chemotherapy TnT was normal (ie, ≤14 ng/L) in 90% of all participants (median 6 [IQR: 4-9] ng/L), but by cycle 4 of chemotherapy, 49% had TnT >14 ng/L (median: 14 [IQR: 9-21] ng/L). This rose to 81% by cycle 6 (median: 33 [IQR: 16-36] ng/L) and remained elevated 1 month after anthracycline chemotherapy in 76% (median 24 [IQR: 15-59] ng/L (Supplemental Tables 8 and 9). Figure 2 shows the effect of RIC on TnT concentrations with no difference between the 2 groups in TnT. Mixed-effects regression, which includes all time points,
showed no difference in TnT (RIC vs sham, mean difference 3.15 ng/L; 95% CI: −0.04 to 6.33; \( P = 0.053 \)).

**Pre- and immediately post-chemotherapy TnT.** There was no difference between TnT in blood drawn immediately before each anthracycline exposure or the sample taken immediately after the end of infusions (mean difference 1.6 ng/L; 95% CI: −0.39 to 3.59; \( P = 0.12 \)) at any stage in the chemotherapy regimen (Supplemental Figure 2, Supplemental Table 8).

Post-chemotherapy TnT samples were collected at a median time of 134 (IQR: 59.5-222.5) minutes from
the end of the doxorubicin injection/infusion (range 13 to 120 minutes). This was a deviation from the planned study protocol for post-dosing blood test sampling (blood test >3 hours up to 24 hours post-chemotherapy) and reflected unwillingness of patients to remain in the hospital for >3 hours.

All results for TnT used in the analysis of RIC were derived from the blood sample taken immediately before each cycle of chemotherapy.

SECONDARY OUTCOMES. cMyC and NT-proBNP. Pre- and post-chemotherapy cMyC concentrations followed a similar pattern to that seen for TnT during chemotherapy with a statistically significant higher proportional increase from baseline for cMyC compared with TnT at each chemotherapy cycle. In C, the peak concentration for each biomarker was identified and the peak:baseline concentration ratio compared. There was a 4-fold median increase from baseline to peak concentration for cMyC vs a 2-fold median increase for TnT (mean 4-fold), which was significant (Wilcoxon signed rank; \( P < 0.001 \)). In D, mixed-effect regression analysis showed cMyC levels were on average 4.17 ng/L higher in RIC compared with sham, which did not reach statistical significance (95% CI: −0.12 to 8.45 ng/L; \( P = 0.056 \)). Abbreviations as in Figure 1.

FIGURE 3  cMyC and RIC

The figure shows a comparison of TnT and cMyC (A to C) and the effect of RIC on cMyC (D). In A and B, cMyC follows a similar pattern of rise as TnT during chemotherapy with a statistically significant higher proportional increase from baseline for cMyC compared with TnT at each chemotherapy cycle. In C, the peak concentration for each biomarker was identified and the peak:baseline concentration ratio compared. There was a 4-fold median increase from baseline to peak concentration for cMyC vs a 2-fold median increase for TnT (mean 4-fold), which was significant (Wilcoxon signed rank; \( P < 0.001 \)). In D, mixed-effect regression analysis showed cMyC levels were on average 4.17 ng/L higher in RIC compared with sham, which did not reach statistical significance (95% CI: −0.12 to 8.45 ng/L; \( P = 0.056 \)). Abbreviations as in Figure 1.

Echocardiography. There was no significant difference between the mean LVEF or change in (ΔLVEF) at 3M and 12M between the 2 groups (3M mean LVEF difference −0.8%; 95% CI: −4.4% to 2.8%; \( P = 0.65 \), 12M mean LVEF difference 0.3%; 95% CI: −3.5% to 4.1%; \( P = 0.86 \); 3M ΔLVEF difference 2.3%; 95% CI: −1.4% to 6.1%; \( P = 0.22 \), 12M ΔLVEF difference −0.2%; 95% CI: −4.3% to 3.9%; \( P = 0.93 \)) (Supplemental Table 12).

However, in 3 patients (6% of group; 2 RIC) who developed clinical HF during chemotherapy, changes in LVEF were noted: with a 12% decline in LVEF in 1 patient and 2 with a 7% LVEF decline to a level <50%. An additional 6 patients (4 RIC) developed
The figure shows Kaplan-Meier curves for major adverse cardiovascular events (MACE) or cancer death (A), MACE (B), and cancer deaths (C) in RIC vs sham. There were 14 events up to 1 year (11 vs 3 events, RIC vs sham) that reached statistical significance (HR: 0.25; 95% CI: 0.07-0.899; P = 0.034). RIC = remote ischemic conditioning.
asymptomatic declines in LVEF of >10% in the follow-up period.

There were no significant differences between the 2 groups in the absolute GLS, ΔGLS, and relative change in GLS from baseline at 3M or 12M post-chemotherapy (3M P = 0.79; P = 0.38; P = 0.44, respectively; 12M P = 0.10; P = 0.22; P = 0.27, respectively).

CLINICAL EVENTS. Kaplan-Meier curves of cardiovascular events and cancer deaths are shown in Figure 4 and summarized in Table 2. The combined endpoint of MACE or cancer deaths was more common in the RIC group at 1 year (11 vs 3; HR: 0.25; 95% CI: 0.07-0.90; P = 0.034). Deaths were notified by the treating oncologists and flagged on the electronic medical record. There were 9 deaths, attributed to progression of disease and classified as “expected”; there were no cancer-related deaths. Adjudication of events was undertaken by trial clinicians (J.M.W., M.M., and R.C.) from the electronic medical record and subsequently reviewed by the DMC. Clinical serious adverse events are shown in Supplemental Table 14. The most common adverse event was infection; this occurred in 35 patients with 21 (75%) in RIC and 14 (52%) in sham group.

ARRHYTHMIAS. Forty-four patients had ECG monitoring (21 vs 23, RIC vs sham); there were no significant differences between the 2 groups in arrhythmia incidence (Supplemental Table 15).

Twelve patients had nonsustained ventricular tachycardia (5 RIC vs 7 sham), 2 of whom required treatment with beta-blockers.

DISCUSSION

This was the first study to investigate RIC in adult cancer patients receiving anthracycline chemotherapy using blood biomarker changes as a marker of cardiac injury. The study was terminated early due to the global COVID-19 pandemic. The intervention was successfully applied to patients (Table 1), but no difference in the extent of biomarker rise between the RIC and sham treatments was detected (Central Illustration), nor were there any differences in cardiac function. Only 3 patients had an acute, severe clinical cardiac toxicity event with HF, limiting the possible interpretation of the potential for RIC in this scenario.

Nevertheless, reliable insights into the pattern of contemporary cardiac biomarkers during exposure to anthracyclines has been gained, with 76% patients having a positive TnT 1-month post-chemotherapy; previous earlier studies showed only 30% positivity at that point.²⁵ It can be reliably stated from this study that RIC does not appear to attenuate the TnT or cMyC rise with chemotherapy. This admittedly small study did not stratify for cancer severity at randomization, but RIC was associated with a tendency toward earlier cancer deaths and a signal (not significant) for increased infection risk. The premature, forced termination of the study and the imbalance of cancer severity at randomization preclude a robust interpretation of these clinical events.

Are blood cardiac biomarkers the correct tool for the detection of cardiotoxicity in cancer treatment? Cardiac biomarkers TnT and cMyC rose after the third or fourth cycle of doxorubicin, peaking at the last cycle, and remaining elevated 4 weeks after completing chemotherapy. There were no acute changes in the biomarkers in the hours after anthracycline therapy. Although cMyC is a sensitive biomarker, it did not add significantly to the ability to discriminate between treatment arms. Biomarker increases are generally associated with worse late outcomes for patients,²⁷ and biomarkers were a reasonable surrogate assessed in our study.

Our study was underpowered, but other factors may have contributed to our results. In animal studies, the myocardial injury is likely to be large and acute; and these studies used higher doses of anthracyclines²⁵-²⁷ or intracoronary administration²⁵ in an experimental model originally developed to study HF.²⁸ In our study of cancer patients, cardiac injury is more likely to be gradual and progressive. Under such circumstances, the cardiac injury may have been too small to detect any effect from RIC. The extraordinary sensitivity of current biomarkers (a rise of 3.9 ng/L and 41 ng/L per µg of injured myocardium for TnT and cMyC, respectively²⁹) suggests that in this study, the increases in cardiac biomarkers documented would result in the amount of myocardium injured to be too small to detect functional changes and too small to allow an intervention, such as RIC, to

---

**Table 2** MACE or Cancer Deaths Up to 1 Year

<table>
<thead>
<tr>
<th></th>
<th>All Patients</th>
<th>RIC</th>
<th>Sham</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(N = 55)</td>
<td>(n = 28)</td>
<td>(n = 27)</td>
<td></td>
</tr>
<tr>
<td>All events</td>
<td>14 (25)</td>
<td>11 (39)</td>
<td>3 (19)</td>
<td>0.034</td>
</tr>
<tr>
<td>MACE</td>
<td>5 (9)</td>
<td>3 (11)</td>
<td>2 (7)</td>
<td>0.44</td>
</tr>
<tr>
<td>Arrhythmias</td>
<td>2 (4)</td>
<td>1 (4)</td>
<td>1 (4)</td>
<td></td>
</tr>
<tr>
<td>Heart failure</td>
<td>3 (6)</td>
<td>2 (7)</td>
<td>1 (4)</td>
<td></td>
</tr>
<tr>
<td>Cancer deaths</td>
<td>9 (16)</td>
<td>8 (29)</td>
<td>1 (4)</td>
<td>0.043</td>
</tr>
</tbody>
</table>

Values are n (%). P value obtained from Cox regression analysis.

MACE = major adverse cardiovascular events; RIC = remote ischemic conditioning.
Anthracycline chemotherapy led to a significant rise in cardiac biomarkers with both high sensitivity troponin T (TnT) and the novel biomarker cardiac myosin binding protein C (cMyC) rising early during first few cycles of chemotherapy. In this randomized, single blind, sham-control trial, remote ischemic conditioning (RIC), delivered via a blood pressure cuff on the arm during chemotherapy, had no effect on the levels of biomarkers as markers of cardiotoxicity. SD = standard deviation; SE = standard error.
be clinically detectable. An analogous situation was encountered in the recently published study of RIC in acute infarction, where a neutral result was attributed to the very low incidence of cardiac events.\textsuperscript{30,31} Thus, blood cardiac biomarkers may be indicators of a risk for the development of cardiac damage but are likely to be insufficient on their own to define clinically relevant cardiotoxicity, at least in the short term.

The trial included any patient undergoing anthracycline chemotherapy with a balanced distribution of cancer types and dosing (>300 mg/m\textsuperscript{2}) across both groups. However, 54% of RIC patients had metastatic disease compared with 37% in the sham group, producing an imbalance in severity of disease at randomization. This imbalance may account for more cancer deaths in the RIC group up to 12 months post-chemotherapy. The cancer deaths were associated with progression of disease. Ongoing analysis, beyond 12 months, has revealed equalization of the number of deaths. The relationship, if any, of RIC to early deaths seen in this small study is not established, but such theoretical risks have been previously raised.\textsuperscript{32} Clinical adverse events were similar between the 2 groups, and of those, the majority were due to admissions with fever or infection (Supplemental Table 14). Nevertheless, these data imply caution in the future investigation of potentially cardioprotective interventions in the context of cancer therapy, where inadvertent cancer cell protection or interference with general responses to injury or infection may have unexpected clinical consequences.

STUDY LIMITATIONS. This phase II study was underpowered to demonstrate an effect of RIC on classically defined cardiotoxicity, or HF, which occurred in only 6% of the total cohort. Study enrolment was halted due to the COVID-19 pandemic, and the DMC at the time of halting the trial adjudicated that the primary endpoint of a difference in TnT leak between the 2 groups was unlikely to be achieved and, combined with a signal for early complications, recommended cessation of the trial. A signal for early cancer deaths in the RIC group is worthy of note, but the study was unbalanced with regard to cancer severity at randomization, limiting the interpretation of this observation. No consistent changes in LVEF were documented in the majority of our patients, but our study relied upon echocardiography undertaken in the clinical service department and with the acknowledged measurement variability that this approach might produce, small changes in LVEF may have been missed.

CONCLUSIONS

Our observation of the almost universal, progressive rise in cardiac biomarkers with increasing doses of anthracyclines, adds to our understanding of the effects chemotherapy, but confirms the difficulty in using blood biomarkers for clinical definitions of cardiotoxicity. This supports the potential approach of including imaging parameters in the definition of cardiotoxicity.\textsuperscript{33}

Remote ischemic conditioning did not reduce the progressive rise in cardiac blood biomarkers during high-dose anthracycline chemotherapy in these patients with severe cancers. Its potential role in severe acute cardiotoxicity cannot be inferred from our data. Larger studies combining results from biomarkers and more sensitive measures of cardiac function over longer periods of time post-chemotherapy are going to be needed to resolve the significance of TnT increases during therapy and the predictive “safe” upper limits for the biomarkers. In this regard, we await with interest the RESILIENCE clinical study (Remote Ischemic Conditioning in Lymphoma Patients Receiving Anthracyclines; NCT05223413), which will involve a larger group of patients with a single cancer type, followed with multimodality cardiac assessments over a longer period.

ACKNOWLEDGMENTS The authors would like to acknowledge the help and contribution made to this study by their medical oncology colleagues including Prof Daniel Hochhauser, Dr Sandra Strauss, Prof Jeremy Whelan, Dr Jonathan Lambert, Dr Kirit Adesha, and their teams at UCLH. The authors would also like to thank the patients who agreed to participate. The authors thank Prof Michael Marber, and Dr Bashir Albour from Kings College, London, for their advice and help with the cardiac myosin-binding protein C analyses.

FUNDING SUPPORT AND AUTHOR DISCLOSURES

Funding for this study was from the University College Hospital Charity (Reg No. 1165398), via the McClean Greenbaum Legacy (Fund 1425) and from University College Hospital National Institute for Health Research Biomedical Research Centre (NIHR BRC). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

ADDRESS FOR CORRESPONDENCE: Prof Derek Yellon, OR Prof Malcolm Walker, The Hatter Cardiovascular Institute, University College London Institute of Cardiovascular Science, 67 Chenes Mews, London WC1E 6HX, United Kingdom. E-mail: d.yellon@ucl.ac.uk. OR malcolm.walker@ucl.ac.uk.
RIC With Anthracycline Therapy

JACC: CARDIOONCOLOGY, VOL. 5, NO. 3, 2023
JUNE 2023:343-355

PERSPECTIVES

COMPETENCY IN MEDICAL KNOWLEDGE: In pa-
tients receiving anthracycline chemotherapy, there is an
early rise in biomarkers of myocardial injury that starts
with chemotherapy and persists during follow-up. In this
proof-of-concept, phase II, single-blind, randomized
treatment, RIC did not attenuate a rise in markers of
injury, nor were there any changes in cardiac function
overall. RIC, although a promising experimental tool for
cardioprotection, should be considered with caution in
the context of cancer therapy, and any contribution to
worse early outcomes needs to be more fully understood.

TRANSLATIONAL OUTLOOK: Future studies should
concentrate on delineating the characteristics and
mechanisms of the increase in biomarkers, and their role
in predicting cardiotoxicity, as well as identifying new
strategies of cardioprotection, which should include
consideration of late manifestations of cardiac injury,
while maintaining the anticancer efficacy of
chemotherapy.

REFERENCES

detection of anthracycline cardiotoxicity and
improvement with heart failure therapy. Circula-
2. Totzeck M, Schuler M, Stuschke M, et al. Cardio-
oncology strategies for management of cancer-
therapy related cardiovascular disease. Int J
Cardiol. 2019;280:163-175.
3. Cardinale D, Colombo A, Sandri MT, et al. Preven-
tion of high-dose chemotherapy-induced
cardiotoxicity in high-risk patients by angiotensin-
cardiac dysfunction during adjuvant breast cancer
therapy (PRADA): a 2 × 2 factorial, randomized,
placebo-controlled, double-blind clinical trial of
5. Tebbi CK, London WB, Friedman D, et al. Dext-
rozoxane-associated risk for acute myeloid leuke-
emia/myelodysplastic syndrome and other
secondary malignancies in pediatric Hodgkin’s
6. Shaikh F, Dupuis LL, Alexander S, Gupta A,
Mertens L, Nathan PC. Cardioprotection and sec-
ond malignant neoplasms associated with dex-
rozoxane in children receiving anthracycline
chemotherapy: a systematic review and meta-
ischemic conditioning. J Am Coll Cardiol. 2015;65:
177-195.
8. Cardillo L, Malik A, Haasenloy DJ. Protection of
organs other than the heart by remote ischemic
9. Haasenloy DJ, Yellon DM. Ischemic condi-
by mdivi-1: a mitochondrial division/mitophagy
a target for protection against cardiomyopathy.
Proc Natl Acad Sci U S A. 2019;116(7):2672-
2680.
Ischaemic preconditioning protects cardiomyocytes from anthracycline-induced toxicity
via the PI3K pathway. Cardiovasc Drugs Ther.
ischemic pre-conditioning attenuates adverse
cardiac remodeling and mortality following doxo-
rubicin administration in mice. J Am Coll Cardiol
Repeated remote ischemic conditioning reduces
doxorubicin-induced cardiotoxicity. J Am Coll
Cardiol CardioOnc. 2020;2(1):41-52.
15. Galán-Arriola C, Villena-Gutiérrez R, Higuero-
Verdejo M, et al. Remote ischemic preconditioning
ameliorates anthracycline-induced cardiotoxicity
and preserves mitochondrial integrity. Cardiovasc
of remote ischaemic conditioning in oncology pa-
tients undergoing chemotherapy: rationale and
design of the ERIC-ONC study - a single-center,
blinded, randomized controlled trial. Clin Cardiol.
17. Bell RM, Rear R, Cunningham J, et al. Effect of
remote ischaemic conditioning on contrast-
induced nephropathy in patients undergoing
elective coronary angiography (ERIC-CON): rationale
and study design of a randomised single-arm,
double-blind placebo-controlled trial. Clin Res
troponin assays: guide to understanding analytical
characteristics and their impact on clinical care.
development and application of a high-sensitivity
immunoassay for cardiac myosin-binding protein
10.1016/j.trsl.2015.11.008
Direct comparison of cardiac myosin-binding pro-
tein C with cardiac troponins for the early diag-
osis of acute myocardial infarction. Circulation.
2017;136(16):1495-1508.
gement of asymptomatic arrhythmias: a Euro-
pean Heart Rhythm Association (EHRA) consensus
document, endorsed by the Heart Failure Associ-
ation (HFA), Heart Rhythm Society (HRS), Asia
Pacific Heart Rhythm Society (APHRS), Cardiac
Arrhythmia Society of Southern Africa (CASSA),
and Latin America Heart Rhythm Society (LAHRS).
10.1093/europace/euz046
22. Haasenloy DJ, Mwamure PK, Venugopal V,
et al. Effect of remote ischemic preconditioning
on myocardial injury in patients undergoing coro-
ary artery bypass graft surgery: a randomised
23. Hoole SP, Heck PM, Sharples L, et al. Cardiac
remote ischemic preconditioning in coronary
stening (CRISP stent) study. A prospective, ran-
820-827.
Remote ischemic conditioning before hospital
admission, as a complement to angioplasty, and
effect on myocardial salvage in patients with acute
myocardial infarction: a randomised controlled trial.
Prognostic value of troponin I in cardiac risk
stratification of cancer patients undergoing high-
2749-2754.
26. Käser TE, Alauor B, Marber M. Cardiac myosin-
binding protein C: how a novel biomarker could


**KEY WORDS** anthracycline, cardiac function, cardioprotection, cardiotoxicity, remote ischemic conditioning, troponin

**APPENDIX** For supplemental figures and tables, please see the online version of this paper.